Baseline Mean Hemoglobin in FAIR-HF Trial
The baseline mean hemoglobin level in the FAIR-HF trial was approximately 10-12 g/dL, with patients enrolled having hemoglobin levels ≥12 g/dL or lower depending on iron deficiency status. 1
Specific Baseline Hemoglobin Data
The FAIR-HF trial enrolled patients with chronic heart failure and iron deficiency, with or without anemia. 1
Key baseline characteristics:
Patients were stratified based on anemia status, with enrollment including both anemic (hemoglobin <12 g/dL in women, <13 g/dL in men) and non-anemic patients with iron deficiency 2
The trial specifically included patients with mean baseline hemoglobin levels in the range of 10-12 g/dL, consistent with the enrollment criteria for heart failure patients with moderate anemia 1
Iron deficiency was defined as ferritin <100 ng/mL or ferritin 100-300 ng/mL with transferrin saturation <20%, which was the primary inclusion criterion rather than a specific hemoglobin threshold 1, 3
Clinical Context
The FAIR-HF trial demonstrated that 50% of patients treated with intravenous ferric carboxymaltose reported being much or moderately improved compared to 28% receiving placebo (odds ratio 2.51,95% CI 1.75-3.61), regardless of baseline anemia status 2
Important distinction: The trial's design focused on iron deficiency rather than anemia severity, allowing enrollment of patients with hemoglobin ≥12 g/dL who had iron deficiency, which differentiates it from earlier erythropoiesis-stimulating agent trials that required lower hemoglobin thresholds 1, 2